메뉴 건너뛰기




Volumn 26, Issue 6, 2013, Pages 852-860

Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma

Author keywords

Melanoma of unknown primary; Mutation profile; Sequencing

Indexed keywords

B RAF KINASE;

EID: 84886239930     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12153     Document Type: Article
Times cited : (49)

References (54)
  • 1
    • 84864059882 scopus 로고    scopus 로고
    • Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma
    • Azimi, F., Scolyer, R.A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S.W., Saw, R.P., and Thompson, J.F. (2012). Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J. Clin. Oncol. 30, 2678-2683.
    • (2012) J. Clin. Oncol. , vol.30 , pp. 2678-2683
    • Azimi, F.1    Scolyer, R.A.2    Rumcheva, P.3    Moncrieff, M.4    Murali, R.5    McCarthy, S.W.6    Saw, R.P.7    Thompson, J.F.8
  • 2
    • 0034831138 scopus 로고    scopus 로고
    • Segmental duplications: organization and impact within the current human genome project assembly
    • Bailey, J.A., Yavor, A.M., Massa, H.F., Trask, B.J., and Eichler, E.E. (2001). Segmental duplications: organization and impact within the current human genome project assembly. Genome Res. 11, 1005-1017.
    • (2001) Genome Res. , vol.11 , pp. 1005-1017
    • Bailey, J.A.1    Yavor, A.M.2    Massa, H.F.3    Trask, B.J.4    Eichler, E.E.5
  • 3
    • 84861427327 scopus 로고    scopus 로고
    • Melanoma genome sequencing reveals frequent PREX2 mutations
    • Berger, M.F., Hodis, E., Heffernan, T.P. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
    • (2012) Nature , vol.485 , pp. 502-506
    • Berger, M.F.1    Hodis, E.2    Heffernan, T.P.3
  • 4
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer, J.R., Tykodi, S.S., Chow, L.Q. et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465.
    • (2012) N. Engl. J. Med. , vol.366 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 5
    • 61449090474 scopus 로고    scopus 로고
    • Phase I/II trial of tremelimumab in patients with metastatic melanoma
    • Camacho, L.H., Antonia, S., Sosman, J. et al. (2009). Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27, 1075-1081.
    • (2009) J. Clin. Oncol. , vol.27 , pp. 1075-1081
    • Camacho, L.H.1    Antonia, S.2    Sosman, J.3
  • 8
    • 27844567142 scopus 로고    scopus 로고
    • Distinct sets of genetic alterations in melanoma
    • Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
    • (2005) N. Engl. J. Med. , vol.353 , pp. 2135-2147
    • Curtin, J.A.1    Fridlyand, J.2    Kageshita, T.3
  • 9
    • 33749021085 scopus 로고    scopus 로고
    • Somatic activation of KIT in distinct subtypes of melanoma
    • Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
    • (2006) J. Clin. Oncol. , vol.24 , pp. 4340-4346
    • Curtin, J.A.1    Busam, K.2    Pinkel, D.3    Bastian, B.C.4
  • 10
    • 0000521726 scopus 로고
    • Malignant melanoma of unknown primary origin
    • Dasgupta, T., Bowden, L., and Berg, J.W. (1963). Malignant melanoma of unknown primary origin. Surg. Gynecol. Obstet. 117, 341-345.
    • (1963) Surg. Gynecol. Obstet. , vol.117 , pp. 341-345
    • Dasgupta, T.1    Bowden, L.2    Berg, J.W.3
  • 11
    • 84865839400 scopus 로고    scopus 로고
    • Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapy
    • Dutton-Regester, K., and Hayward, N.K. (2012). Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapy. Adv. Pharmacol. 65, 399-435.
    • (2012) Adv. Pharmacol. , vol.65 , pp. 399-435
    • Dutton-Regester, K.1    Hayward, N.K.2
  • 12
    • 84857443939 scopus 로고    scopus 로고
    • Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene
    • Dutton-Regester, K., Aoude, L.G., Nancarrow, D.J. et al. (2012a). Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene. Genes Chromosom. Cancer 51, 452-461.
    • (2012) Genes Chromosom. Cancer , vol.51 , pp. 452-461
    • Dutton-Regester, K.1    Aoude, L.G.2    Nancarrow, D.J.3
  • 13
    • 84861893379 scopus 로고    scopus 로고
    • A high-throughput panel for identifying clinically relevant mutation profiles in melanoma
    • Dutton-Regester, K., Irwin, D., Hunt, P. et al. (2012b). A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol. Cancer Ther. 11, 888-897.
    • (2012) Mol. Cancer Ther. , vol.11 , pp. 888-897
    • Dutton-Regester, K.1    Irwin, D.2    Hunt, P.3
  • 14
    • 0013773589 scopus 로고
    • Spontaneous regression of cancer
    • Everson, T.C. (1964). Spontaneous regression of cancer. Ann. N. Y. Acad. Sci. 114, 721-735.
    • (1964) Ann. N. Y. Acad. Sci. , vol.114 , pp. 721-735
    • Everson, T.C.1
  • 15
    • 84861083983 scopus 로고    scopus 로고
    • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
    • Falchook, G.S., Long, G.V., Kurzrock, R. et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
    • (2012) Lancet , vol.379 , pp. 1893-1901
    • Falchook, G.S.1    Long, G.V.2    Kurzrock, R.3
  • 16
    • 84868224906 scopus 로고    scopus 로고
    • Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    • Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
    • (2012) N. Engl. J. Med. , vol.367 , pp. 1694-1703
    • Flaherty, K.T.1    Infante, J.R.2    Daud, A.3
  • 17
    • 84862702937 scopus 로고    scopus 로고
    • Genomic characterisation of acral melanoma cell lines
    • Furney, S.J., Turajlic, S., Fenwick, K. et al. (2012). Genomic characterisation of acral melanoma cell lines. Pigment Cell Melanoma Res. 25, 488-492.
    • (2012) Pigment Cell Melanoma Res. , vol.25 , pp. 488-492
    • Furney, S.J.1    Turajlic, S.2    Fenwick, K.3
  • 19
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
    • Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3
  • 20
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
    • (2010) N. Engl. J. Med. , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 21
    • 84864258996 scopus 로고    scopus 로고
    • A landscape of driver mutations in melanoma
    • Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
    • (2012) Cell , vol.150 , pp. 251-263
    • Hodis, E.1    Watson, I.R.2    Kryukov, G.V.3
  • 22
    • 84864722943 scopus 로고    scopus 로고
    • NRAS mutation status is an independent prognostic factor in metastatic melanoma
    • Jakob, J.A., Bassett Jr, R.L., Ng, C.S. et al. (2012). NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023.
    • (2012) Cancer , vol.118 , pp. 4014-4023
    • Jakob, J.A.1    Bassett Jr, R.L.2    Ng, C.S.3
  • 23
    • 79953322223 scopus 로고    scopus 로고
    • Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature
    • Kamposioras, K., Pentheroudakis, G., Pectasides, D., and Pavlidis, N. et al. (2011). Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit. Rev. Oncol. Hematol. 78, 112-126.
    • (2011) Crit. Rev. Oncol. Hematol. , vol.78 , pp. 112-126
    • Kamposioras, K.1    Pentheroudakis, G.2    Pectasides, D.3    Pavlidis, N.4
  • 25
    • 84865684161 scopus 로고    scopus 로고
    • Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
    • Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
    • (2012) Nat. Genet. , vol.44 , pp. 1006-1014
    • Krauthammer, M.1    Kong, Y.2    Ha, B.H.3
  • 26
    • 39149089000 scopus 로고    scopus 로고
    • Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma
    • Lee, C.C., Faries, M.B., Wanek, L.A., and Morton, D.L. et al. (2008). Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J. Clin. Oncol. 26, 535-541.
    • (2008) J. Clin. Oncol. , vol.26 , pp. 535-541
    • Lee, C.C.1    Faries, M.B.2    Wanek, L.A.3    Morton, D.L.4
  • 27
    • 67649884743 scopus 로고    scopus 로고
    • Fast and accurate short read alignment with Burrows-Wheeler transform
    • Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760.
    • (2009) Bioinformatics , vol.25 , pp. 1754-1760
    • Li, H.1    Durbin, R.2
  • 30
    • 84868120907 scopus 로고    scopus 로고
    • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    • Long, G.V., Trefzer, U., Davies, M.A. et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
    • (2012) Lancet Oncol. , vol.13 , pp. 1087-1095
    • Long, G.V.1    Trefzer, U.2    Davies, M.A.3
  • 32
    • 84872595484 scopus 로고    scopus 로고
    • BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma
    • Mann, G.J., Pupo, G.M., Campain, A.E et al. (2013). BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J. Invest. Dermatol. 133, 509-517.
    • (2013) J. Invest. Dermatol. , vol.133 , pp. 509-517
    • Mann, G.J.1    Pupo, G.M.2    Campain, A.E.3
  • 33
    • 70149093912 scopus 로고    scopus 로고
    • Recurring mutations found by sequencing an acute myeloid leukemia genome
    • Mardis, E.R., Ding, L., Dooling, D.J. et al. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066.
    • (2009) N. Engl. J. Med. , vol.361 , pp. 1058-1066
    • Mardis, E.R.1    Ding, L.2    Dooling, D.J.3
  • 35
    • 84856268319 scopus 로고    scopus 로고
    • Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
    • Nikolaev, S.I., Rimoldi, D., Iseli, C. et al. (2012). Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44, 133-139.
    • (2012) Nat. Genet. , vol.44 , pp. 133-139
    • Nikolaev, S.I.1    Rimoldi, D.2    Iseli, C.3
  • 36
    • 2942533921 scopus 로고    scopus 로고
    • Microarray expression profiling in melanoma reveals a BRAF mutation signature
    • Pavey, S., Johansson, P., Packer, L. et al. (2004). Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23, 4060-4067.
    • (2004) Oncogene , vol.23 , pp. 4060-4067
    • Pavey, S.1    Johansson, P.2    Packer, L.3
  • 37
    • 74449093973 scopus 로고    scopus 로고
    • A comprehensive catalogue of somatic mutations from a human cancer genome
    • Pleasance, E.D., Cheetham, R.K., Stephens, P.J. et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196.
    • (2010) Nature , vol.463 , pp. 191-196
    • Pleasance, E.D.1    Cheetham, R.K.2    Stephens, P.J.3
  • 39
    • 0017344834 scopus 로고
    • Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance
    • Ridolfi, R.L., Rosen, P.P., and Thaler, H. (1977). Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer 39, 164-171.
    • (1977) Cancer , vol.39 , pp. 164-171
    • Ridolfi, R.L.1    Rosen, P.P.2    Thaler, H.3
  • 40
    • 0032589240 scopus 로고    scopus 로고
    • Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells
    • Rizos, H., Darmanian, A.P., Indsto, J.O., Shannon, J.A., Kefford, R.F., and Mann, G.J. (1999). Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. Melanoma Res. 9, 10-19.
    • (1999) Melanoma Res. , vol.9 , pp. 10-19
    • Rizos, H.1    Darmanian, A.P.2    Indsto, J.O.3    Shannon, J.A.4    Kefford, R.F.5    Mann, G.J.6
  • 41
    • 0023136996 scopus 로고
    • Malignant melanoma primary in lymph node. The case of the missing link
    • Shenoy, B.V., Fort 3rd, L., and Benjamin, S.P. (1987). Malignant melanoma primary in lymph node. The case of the missing link. Am. J. Surg. Pathol. 11, 140-146.
    • (1987) Am. J. Surg. Pathol. , vol.11 , pp. 140-146
    • Shenoy, B.V.1    Fort III, L.2    Benjamin, S.P.3
  • 42
    • 79952769109 scopus 로고    scopus 로고
    • Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation
    • Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., and Yamazaki, N. (2011). Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am. J. Pathol. 178, 1395-1402.
    • (2011) Am. J. Pathol. , vol.178 , pp. 1395-1402
    • Shibata, T.1    Kokubu, A.2    Miyamoto, M.3    Sasajima, Y.4    Yamazaki, N.5
  • 43
    • 0013815469 scopus 로고
    • Spontaneous regression of primary malignant melanomas with regional metastases
    • Smith Jr, J.L., and Stehlin Jr, J.S. (1965). Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 18, 1399-1415.
    • (1965) Cancer , vol.18 , pp. 1399-1415
    • Smith Jr, J.L.1    Stehlin Jr, J.S.2
  • 44
    • 34047258036 scopus 로고    scopus 로고
    • Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays
    • Stark, M., and Hayward, N. (2007). Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 67, 2632-2642.
    • (2007) Cancer Res. , vol.67 , pp. 2632-2642
    • Stark, M.1    Hayward, N.2
  • 45
    • 84856273432 scopus 로고    scopus 로고
    • Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing
    • Stark, M.S., Woods, S.L., Gartside, M.G. et al. (2012). Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 44, 165-169.
    • (2012) Nat. Genet. , vol.44 , pp. 165-169
    • Stark, M.S.1    Woods, S.L.2    Gartside, M.G.3
  • 46
    • 34547697828 scopus 로고    scopus 로고
    • Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells
    • Stefansson, B., and Brautigan, D.L. (2007). Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells. Cell Cycle 6, 1386-1392.
    • (2007) Cell Cycle , vol.6 , pp. 1386-1392
    • Stefansson, B.1    Brautigan, D.L.2
  • 47
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian, S.L., Hodi, F.S., Brahmer, J.R. et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
    • (2012) N. Engl. J. Med. , vol.366 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 48
    • 80255132732 scopus 로고    scopus 로고
    • Extensive screening for primary tumor is redundant in melanoma of unknown primary
    • Tos, T., Klyver, H., and Drzewiecki, K.T. (2011). Extensive screening for primary tumor is redundant in melanoma of unknown primary. J. Surg. Oncol. 104, 724-727.
    • (2011) J. Surg. Oncol. , vol.104 , pp. 724-727
    • Tos, T.1    Klyver, H.2    Drzewiecki, K.T.3
  • 49
    • 84863393606 scopus 로고    scopus 로고
    • Whole genome sequencing of matched primary and metastatic acral melanomas
    • Turajlic, S., Furney, S.J., Lambros, M.B. et al. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 22, 196-207.
    • (2012) Genome Res. , vol.22 , pp. 196-207
    • Turajlic, S.1    Furney, S.J.2    Lambros, M.B.3
  • 52
    • 77956534324 scopus 로고    scopus 로고
    • ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
    • Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164.
    • (2010) Nucleic Acids Res. , vol.38
    • Wang, K.1    Li, M.2    Hakonarson, H.3
  • 53
    • 85027946522 scopus 로고    scopus 로고
    • Exome sequencing identifies GRIN2A as frequently mutated in melanoma
    • Wei, X., Walia, V., Lin, J.C. et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.
    • (2011) Nat. Genet. , vol.43 , pp. 442-446
    • Wei, X.1    Walia, V.2    Lin, J.C.3
  • 54
    • 60849115270 scopus 로고    scopus 로고
    • IDH1 and IDH2 mutations in gliomas
    • Yan, H., Parsons, D.W., Jin, G. et al. (2009). IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773.
    • (2009) N. Engl. J. Med. , vol.360 , pp. 765-773
    • Yan, H.1    Parsons, D.W.2    Jin, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.